Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the…
Aardvark Therapeutics, Inc. (AARD) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data Clinical development of ARD-101 for hyperphagia in Prader-Willi Synd
How this was made
The 30-second read
Why it matters
The regulatory clearance removes a key barrier, likely prompting a share price rally and renewed investor interest.
Market read
Primary catalyst for AARD; limited spillover to broader biotech sector.
What to watch
Potential need for additional safety data could delay trial restart despite the hold being lifted.
Background
Aardvark Therapeutics (Nasdaq: AARD) paused its Phase 3 HERO trial after ECG changes in healthy volunteers. The FDA placed a hold in May 2026, which was lifted on Oct 22, 2026.
Ticker impact
FDA lifted the clinical hold on ARD-101, allowing Aardvark Therapeutics to resume development and potentially restart the Phase 3 trial.
likely upside as investors price the resumption of ARD-101 trials
Regulatory clearance is a material catalyst for a clinical‑stage biotech; the market typically reacts positively to the removal of a hold.
Market effects
May boost sentiment for hunger‑suppression and rare‑disease biotech peers.
Limited to US biotech sector; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
If the upcoming Phase 3 design faces further regulatory hurdles, the lift may be short‑lived.
Key entities
- companyAardvark Therapeutics, Inc.
Clinical‑stage biotech developing ARD-101 for Prader‑Willi Syndrome.
- regulatorFDA
U.S. Food and Drug Administration that lifted the clinical hold.
